Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
8.41
-0.08 (-0.94%)
Nov 4, 2024, 4:00 PM EST - Market closed
Amneal Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Revenue | 2,598 | 2,394 | 2,212 | 2,094 | 1,993 | 1,626 | Upgrade
|
Revenue Growth (YoY) | 12.37% | 8.20% | 5.67% | 5.08% | 22.51% | -2.20% | Upgrade
|
Cost of Revenue | 1,633 | 1,530 | 1,421 | 1,310 | 1,340 | 1,161 | Upgrade
|
Gross Profit | 965.11 | 863.87 | 791.46 | 783.95 | 652.32 | 464.92 | Upgrade
|
Selling, General & Admin | 451.07 | 429.68 | 399.7 | 365.5 | 326.73 | 289.6 | Upgrade
|
Research & Development | 162.81 | 163.95 | 195.69 | 201.85 | 179.93 | 188.05 | Upgrade
|
Other Operating Expenses | 0.07 | -1.14 | -3.96 | - | - | - | Upgrade
|
Operating Expenses | 613.95 | 592.49 | 591.43 | 567.35 | 506.66 | 477.65 | Upgrade
|
Operating Income | 351.16 | 271.38 | 200.03 | 216.6 | 145.66 | -12.73 | Upgrade
|
Interest Expense | -241.88 | -210.63 | -158.38 | -136.33 | -146 | -168.21 | Upgrade
|
Currency Exchange Gain (Loss) | -2.11 | 1.67 | -12.36 | -0.36 | 16.35 | -4.96 | Upgrade
|
Other Non Operating Income (Expenses) | -9.19 | 5.12 | 17.83 | 15.33 | 2.59 | 194.35 | Upgrade
|
EBT Excluding Unusual Items | 97.97 | 67.54 | 47.13 | 95.25 | 18.6 | 8.46 | Upgrade
|
Merger & Restructuring Charges | -2.85 | -1.75 | -2.13 | -9.91 | -11.39 | -39.97 | Upgrade
|
Gain (Loss) on Sale of Assets | 3.8 | - | - | - | 0.12 | 7.26 | Upgrade
|
Asset Writedown | -36.13 | -36.13 | -11.11 | -22.69 | -34.58 | -126.16 | Upgrade
|
Legal Settlements | -95.3 | -1.82 | -269.93 | -25 | -5.86 | -12.44 | Upgrade
|
Other Unusual Items | -52.32 | -37.31 | -1.02 | -10.57 | - | -10.77 | Upgrade
|
Pretax Income | -115.62 | -40.27 | -248.13 | 31.37 | -35.78 | -220.24 | Upgrade
|
Income Tax Expense | 17.58 | 8.45 | 6.66 | 11.2 | -104.36 | 383.33 | Upgrade
|
Earnings From Continuing Operations | -133.2 | -48.72 | -254.79 | 20.17 | 68.58 | -603.57 | Upgrade
|
Minority Interest in Earnings | -41.41 | -35.27 | 124.8 | -9.55 | 22.48 | 241.66 | Upgrade
|
Net Income | -174.62 | -83.99 | -129.99 | 10.62 | 91.06 | -361.92 | Upgrade
|
Net Income to Common | -174.62 | -83.99 | -129.99 | 10.62 | 91.06 | -361.92 | Upgrade
|
Net Income Growth | - | - | - | -88.33% | - | - | Upgrade
|
Shares Outstanding (Basic) | 254 | 176 | 151 | 149 | 147 | 132 | Upgrade
|
Shares Outstanding (Diluted) | 254 | 176 | 151 | 152 | 149 | 132 | Upgrade
|
Shares Change (YoY) | 66.75% | 16.69% | -0.58% | 1.95% | 12.72% | 3.81% | Upgrade
|
EPS (Basic) | -0.69 | -0.48 | -0.86 | 0.07 | 0.62 | -2.74 | Upgrade
|
EPS (Diluted) | -0.69 | -0.48 | -0.86 | 0.07 | 0.61 | -2.74 | Upgrade
|
EPS Growth | - | - | - | -88.52% | - | - | Upgrade
|
Free Cash Flow | 207.43 | 298.78 | 16.3 | 190.88 | 317.17 | -45.48 | Upgrade
|
Free Cash Flow Per Share | 0.82 | 1.70 | 0.11 | 1.26 | 2.13 | -0.34 | Upgrade
|
Gross Margin | 37.15% | 36.09% | 35.78% | 37.44% | 32.74% | 28.59% | Upgrade
|
Operating Margin | 13.52% | 11.34% | 9.04% | 10.35% | 7.31% | -0.78% | Upgrade
|
Profit Margin | -6.72% | -3.51% | -5.88% | 0.51% | 4.57% | -22.25% | Upgrade
|
Free Cash Flow Margin | 7.98% | 12.48% | 0.74% | 9.12% | 15.92% | -2.80% | Upgrade
|
EBITDA | 576.39 | 500.78 | 440.21 | 450 | 381.05 | 230.9 | Upgrade
|
EBITDA Margin | 22.19% | 20.92% | 19.90% | 21.49% | 19.12% | 14.20% | Upgrade
|
D&A For EBITDA | 225.24 | 229.4 | 240.18 | 233.41 | 235.39 | 243.63 | Upgrade
|
EBIT | 351.16 | 271.38 | 200.03 | 216.6 | 145.66 | -12.73 | Upgrade
|
EBIT Margin | 13.52% | 11.34% | 9.04% | 10.35% | 7.31% | -0.78% | Upgrade
|
Effective Tax Rate | - | - | - | 35.69% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.